Comparison of the Effect of the Combination of Sodium Valproate and Sodium Dichloroacetate on the Expression of SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP in Primary Female Glioblastoma Cells with That of Temozolomide.

IF 5.5 3区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmaceutics Pub Date : 2025-09-04 DOI:10.3390/pharmaceutics17091161

Dovydas Gečys, Laimis Akramas, Aidanas Preikšaitis, Ingrida Balnytė, Arūnas Vaitkevičius, Julija Šimienė, Donatas Stakišaitis

{"title":"Comparison of the Effect of the Combination of Sodium Valproate and Sodium Dichloroacetate on the Expression of SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP in Primary Female Glioblastoma Cells with That of Temozolomide.","authors":"Dovydas Gečys, Laimis Akramas, Aidanas Preikšaitis, Ingrida Balnytė, Arūnas Vaitkevičius, Julija Šimienė, Donatas Stakišaitis","doi":"10.3390/pharmaceutics17091161","DOIUrl":null,"url":null,"abstract":"The search for an effective treatment for adult high-grade glioblastoma (GBM) remains urgent. Background/Objectives: The study aimed to determine the expression of carcinogenesis-related genes, such as SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP, in primary glioblastoma (WHO Grade IV; IDH-wild-type) cells from three adult women: GBM5-1, GBM5-2F, and GBM5-3F. Methods: The impact of the combination of sodium valproate and sodium dichloroacetate (2 mM NaVPA-3 mM NaDCA) on the expression of these genes was determined and compared with the effects of 50 µM temozolomide after 24 h of treatment. Results: 2 mM NaVPA-3 mM NaDCA, as well as temozolomide, had individual impacts on the SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP expressions of tested GBM5-1, GBM5-2F, and GBM5-3F primary cells of female GBM patients. Conclusions: The combination of 2 mM NaVPA-3 mM NaDCA may have an advantage in antitumor activity and may be more effective than TMZ; however, the effect is individual.","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 9","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473538/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17091161","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The search for an effective treatment for adult high-grade glioblastoma (GBM) remains urgent. Background/Objectives: The study aimed to determine the expression of carcinogenesis-related genes, such as SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP, in primary glioblastoma (WHO Grade IV; IDH-wild-type) cells from three adult women: GBM5-1, GBM5-2F, and GBM5-3F. Methods: The impact of the combination of sodium valproate and sodium dichloroacetate (2 mM NaVPA-3 mM NaDCA) on the expression of these genes was determined and compared with the effects of 50 µM temozolomide after 24 h of treatment. Results: 2 mM NaVPA-3 mM NaDCA, as well as temozolomide, had individual impacts on the SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP expressions of tested GBM5-1, GBM5-2F, and GBM5-3F primary cells of female GBM patients. Conclusions: The combination of 2 mM NaVPA-3 mM NaDCA may have an advantage in antitumor activity and may be more effective than TMZ; however, the effect is individual.

Abstract Image

查看原文本刊更多论文

丙戊酸钠与二氯乙酸钠联用与替莫唑胺对原发性女性胶质母细胞瘤细胞SLC12A2、SLC12A5、CDH1、CDH2、EZH2、GFAP表达的影响

寻找成人高级别胶质母细胞瘤（GBM）的有效治疗方法仍然是迫切需要的。背景/目的：本研究旨在检测3例成年女性原发性胶质母细胞瘤（WHO IV级；idh -野生型）细胞（GBM5-1、GBM5-2F和GBM5-3F）中SLC12A2、SLC12A5、CDH1、CDH2、EZH2和GFAP等致癌相关基因的表达。方法：测定丙戊酸钠与二氯乙酸钠（2 mM NaVPA-3 mM NaDCA）联合用药对上述基因表达的影响，并与替莫唑胺50µM治疗24 h后的影响进行比较。结果：2 mM NaVPA-3 mM NaDCA及替莫唑胺对女性GBM患者GBM5-1、GBM5-2F、GBM5-3F原代细胞SLC12A2、SLC12A5、CDH1、CDH2、EZH2、GFAP表达均有个体影响。结论：2 mM NaVPA-3 mM NaDCA联合使用可能具有抗肿瘤活性优势，且可能比TMZ更有效；然而，这种影响是个人的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

7.90

自引率

11.10%

发文量

2379

审稿时长

16.41 days

期刊介绍： Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.